Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Deferred Taxes (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Deferred Taxes for 4 consecutive years, with $233000.0 as the latest value for Q4 2025.

  • Quarterly Deferred Taxes fell 41.46% to $233000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, down 5.43% year-over-year, with the annual reading at $2.5 million for FY2025, 5.43% down from the prior year.
  • Deferred Taxes for Q4 2025 was $233000.0 at Centessa Pharmaceuticals, down from $255000.0 in the prior quarter.
  • The five-year high for Deferred Taxes was $1.3 million in Q3 2024, with the low at -$23.5 million in Q2 2023.
  • Average Deferred Taxes over 4 years is -$1.9 million, with a median of $255000.0 recorded in 2025.
  • The sharpest move saw Deferred Taxes tumbled 2040.74% in 2023, then soared 367.11% in 2024.
  • Over 4 years, Deferred Taxes stood at -$2.8 million in 2022, then soared by 94.63% to -$149000.0 in 2023, then skyrocketed by 367.11% to $398000.0 in 2024, then crashed by 41.46% to $233000.0 in 2025.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at $233000.0, $255000.0, and $1.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.